Lower urinary tract symptoms · 2026
Effects of Vibegron, a β3-Adrenoceptor Agonist, on Lower Urinary Tract Dysfunction in Diabetic Rats.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gotoh Daisuke, Torimoto Kazumasa, Ichikawa Kazuki, Tachibana Akira, Nishimura Nobutaka, Oda Yuki, Tomizawa Mitsuru, Onishi Kenta, Morizawa Yosuke, Hori Shunta, Nakai Yasushi, Miyake Makito, Fujimoto Kiyohide
Аннотация
OBJECTIVES: In this study, we aimed to investigate the impact of vibegron, a β3-adrenergic receptor agonist, on lower urinary tract dysfunction in a diabetic rat model.
METHODS: Female rats were categorized into three groups: non-diabetic controls (N), streptozotocin-induced diabetic rats receiving vehicle (D), and diabetic rats treated with vibegron (DV). In the DV group, vibegron was administered orally at 30 mg/kg/day starting 7-8 weeks after diabetes induction. At 8 weeks post-induction, voiding assays, urinary 8-hydroxydeoxyguanosine (8-OHdG) measurements, cystometry, and analysis of bladder mRNA expression levels of ischemia- and inflammatory-related markers were performed.
RESULTS: The 24-h voiding assays showed that Groups D and DV had markedly higher urine volume, average voided volume, voiding frequency, and water intake compared to Group N. Urinary 8-OHdG levels were markedly elevated in Group D than those in Groups N and DV. Group D also exhibited higher opening pressure and non-voiding contractions. Intercontraction intervals, voided volume, post-void residual volume, bladder capacity, and compliance were significantly increased, while voiding efficiency was markedly decreased in Groups D and DV compared to that in Group N. Bladder mRNA expression of hypoxia-inducible factor-1 alpha (Hif1a), vascular endothelial growth factor A (Vegfa), transforming growth factor-beta 1 (Tgfb1), and tumor necrosis factor alpha (Tnfa) was upregulated in Group D compared with that in Groups N and DV.
CONCLUSIONS: These findings suggest that vibegron may be a promising therapeutic option for addressing detrusor overactivity, ischemia, and inflammation of the bladder associated with diabetes mellitus.
METHODS: Female rats were categorized into three groups: non-diabetic controls (N), streptozotocin-induced diabetic rats receiving vehicle (D), and diabetic rats treated with vibegron (DV). In the DV group, vibegron was administered orally at 30 mg/kg/day starting 7-8 weeks after diabetes induction. At 8 weeks post-induction, voiding assays, urinary 8-hydroxydeoxyguanosine (8-OHdG) measurements, cystometry, and analysis of bladder mRNA expression levels of ischemia- and inflammatory-related markers were performed.
RESULTS: The 24-h voiding assays showed that Groups D and DV had markedly higher urine volume, average voided volume, voiding frequency, and water intake compared to Group N. Urinary 8-OHdG levels were markedly elevated in Group D than those in Groups N and DV. Group D also exhibited higher opening pressure and non-voiding contractions. Intercontraction intervals, voided volume, post-void residual volume, bladder capacity, and compliance were significantly increased, while voiding efficiency was markedly decreased in Groups D and DV compared to that in Group N. Bladder mRNA expression of hypoxia-inducible factor-1 alpha (Hif1a), vascular endothelial growth factor A (Vegfa), transforming growth factor-beta 1 (Tgfb1), and tumor necrosis factor alpha (Tnfa) was upregulated in Group D compared with that in Groups N and DV.
CONCLUSIONS: These findings suggest that vibegron may be a promising therapeutic option for addressing detrusor overactivity, ischemia, and inflammation of the bladder associated with diabetes mellitus.